动脉粥样硬化中新兴的循环生物标志物：从分子机制到治疗策略
Emerging Circulating Biomarkers in Atherosclerosis: From Molecular Mechanisms to Therapeutic Strategies.
作者信息
Mandraffino Giuseppe, Mattina Alessandro, Scicali Roberto
机构信息
Internal Medicine Unit, Lipid Center, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Diabetes and Islet Transplantation Unit, Department of Diagnostic and Therapeutic Services, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), UPMC Italy, 90127 Palermo, Italy.
出版信息
Biomolecules. 2022 Jun 9;12(6):809. doi: 10.3390/biom12060809.
Abstract
Atherosclerosis is a long-term damaging process, and its progression leads to cardiovascular system injury [...].
摘要
动脉粥样硬化是一个长期的损害过程，其进展会导致心血管系统损伤[……]。
相似文献
1
Emerging Circulating Biomarkers in Atherosclerosis: From Molecular Mechanisms to Therapeutic Strategies.动脉粥样硬化中新兴的循环生物标志物：从分子机制到治疗策略
Biomolecules. 2022 Jun 9;12(6):809. doi: 10.3390/biom12060809.
2
Circulating Biomarkers Determining Inflammation in Atherosclerosis Progression.循环生物标志物在动脉粥样硬化进展中对炎症的判定作用
Curr Med Chem. 2015;22(22):2619-35. doi: 10.2174/0929867322666150415125828.
3
Circulating Biomarkers for Laboratory Diagnostics of Atherosclerosis-Literature Review.用于动脉粥样硬化实验室诊断的循环生物标志物——文献综述
Diagnostics (Basel). 2022 Dec 13;12(12):3141. doi: 10.3390/diagnostics12123141.
4
[The role of inflammatory biomarkers in cardiovascular risk stratification].[炎症生物标志物在心血管风险分层中的作用]
Wiad Lek. 2017;70(2):182-186.
5
Update on integrated biomarkers for assessment of long-term risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis.初始健康受试者和明显动脉粥样硬化患者心血管并发症长期风险评估的综合生物标志物最新进展。
Ann Med. 2009;41(5):332-43. doi: 10.1080/07853890902769675.
6
Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation.动脉粥样硬化的生物标志物：病理生理作用及药物调节
Curr Opin Lipidol. 2006 Oct;17(5):495-501. doi: 10.1097/01.mol.0000245254.33011.de.
7
Novel Insight into Neuroimmune Regulatory Mechanisms and Biomarkers Linking Major Depression and Vascular Diseases: The Dilemma Continues.对主要抑郁症和血管疾病相关的神经免疫调节机制和生物标志物的新见解：困境仍在继续。
Int J Mol Sci. 2020 Mar 27;21(7):2317. doi: 10.3390/ijms21072317.
8
The relationship between inflammatory and oxidative stress biomarkers, atherosclerosis and rheumatic diseases.炎症和氧化应激生物标志物与动脉粥样硬化和风湿性疾病的关系。
Curr Pharm Des. 2014;20(4):585-600. doi: 10.2174/138161282004140213145806.
9
Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications.动脉僵硬度、动脉粥样硬化与心血管风险：病理生理机制及新出现的临床指征
Vascul Pharmacol. 2016 Feb;77:1-7. doi: 10.1016/j.vph.2015.11.083. Epub 2015 Nov 28.
10
Soluble CD40 receptor is a biomarker of the burden of carotid artery atherosclerosis in subjects at high cardiovascular risk.可溶性CD40受体是心血管疾病高风险人群颈动脉粥样硬化负担的生物标志物。
Atherosclerosis. 2022 Feb;343:1-9. doi: 10.1016/j.atherosclerosis.2022.01.003. Epub 2022 Jan 19.
引用本文的文献
1
Inflammation: Is It a Healer, Confounder, or a Promoter of Cardiometabolic Risks?炎症：它是治疗者、混杂因素还是代谢心血管风险的促进因素？
Biomolecules. 2024 Aug 6;14(8):948. doi: 10.3390/biom14080948.
本文引用的文献
1
Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review.动脉僵硬度与成人起病性血管炎：一项系统评价
Front Med (Lausanne). 2022 May 12;9:824630. doi: 10.3389/fmed.2022.824630. eCollection 2022.
2
Atherosclerosis: Recent developments.动脉粥样硬化：最新进展。
Cell. 2022 May 12;185(10):1630-1645. doi: 10.1016/j.cell.2022.04.004. Epub 2022 May 2.
3
The Fibrinogen-like Domain of ANGPTL3 Facilitates Lipolysis in 3T3-L1 Cells by Activating the Intracellular Erk Pathway.ANGPTL3 的纤维蛋白原样结构域通过激活细胞内 Erk 通路促进 3T3-L1 细胞的脂肪分解。
Biomolecules. 2022 Apr 16;12(4):585. doi: 10.3390/biom12040585.
4
PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy.载脂蛋白 B 降解酶 9 血浆水平与无动脉粥样硬化性心血管疾病史的家族性高胆固醇血症患者的机械血管损伤相关：为期 6 个月的附加性载脂蛋白 B 降解酶 9 抑制剂治疗的结果。
Biomolecules. 2022 Apr 9;12(4):562. doi: 10.3390/biom12040562.
5
Pathophysiology of Atherosclerosis.动脉粥样硬化的病理生理学。
Int J Mol Sci. 2022 Mar 20;23(6):3346. doi: 10.3390/ijms23063346.
6
Characterization of the LPS and 3OHFA Contents in the Lipoprotein Fractions and Lipoprotein Particles of Healthy Men.健康男性脂蛋白部分和脂蛋白颗粒中 LPS 和 3OHFA 含量的特征。
Biomolecules. 2021 Dec 29;12(1):47. doi: 10.3390/biom12010047.
7
Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.脂蛋白(a)-动脉粥样硬化、动脉血栓形成和炎症的十字路口。
Biomolecules. 2021 Dec 24;12(1):26. doi: 10.3390/biom12010026.
8
Integrative Analysis of Multi-Omics and Genetic Approaches-A New Level in Atherosclerotic Cardiovascular Risk Prediction.多组学与遗传学方法的综合分析——动脉粥样硬化性心血管疾病风险预测的新高度。
Biomolecules. 2021 Oct 28;11(11):1597. doi: 10.3390/biom11111597.
9
Cardiorenal Syndrome: New Pathways and Novel Biomarkers.心肾综合征：新途径和新生物标志物。
Biomolecules. 2021 Oct 26;11(11):1581. doi: 10.3390/biom11111581.
10
Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology.在类风湿关节炎和强直性脊柱炎中，经过一年抗 TNF-α 治疗后代谢生物标志物水平的变化：与血管病理生理学的关系。
Biomolecules. 2021 Oct 18;11(10):1535. doi: 10.3390/biom11101535.
Zotero 插件